Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608292 | 0.94 | MAPT (0.41) | EPHX2MAPTLMNAALDH1A1TSHR | |
| SCHEMBL12643038 | 0.87 | EPHX2 (0.44) | EPHX2ALDH1A1CASP2TSHRNAAA | |
| SCHEMBL2608285 | 0.86 | ALDH1A1 (0.39) | EPHX2LMNAALDH1A1TSHR | |
| SCHEMBL10081665 | 0.84 | TSHR (0.43) | EPHX2LMNACASP2TSHRNAAA | |
| SCHEMBL2608288 | 0.83 | TSHR (0.44) | EPHX2MAPTLMNAALDH1A1CASP2 | |
| SCHEMBL12332603 | 0.83 | EPHX2 (0.39) | EPHX2MAPTLMNAALDH1A1CASP2 | |
| SCHEMBL21122975 | 0.81 | GAA (0.45) | EPHX2MAPTALDH1A1CASP2NAAA | |
| SCHEMBL2608281 | 0.81 | LMNA (0.37) | EPHX2MAPTLMNAALDH1A1TSHR | |
| SCHEMBL860819 | 0.80 | EPHX2 (0.43) | EPHX2MAPTLMNAALDH1A1CASP2 | |
| SCHEMBL2608277 | 0.79 | ZDHHC20 (0.49) | EPHX2MAPTLMNAALDH1A1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345180-B2 | Display medium for assessment and method for manufacturing same | ZEON CORPORATION (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20190184732-A1 | DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME | ZEON CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-8262932-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film | FUJIFILM CORPORATION (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8262931-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film | FUJIFILM CORPORATION (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110233464-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | EPHX2 2270/4885MAPT 252/4885LMNA 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.